title: A diet with lactosucrose supplementation ameliorates trinitrobenzene sulfonic acid-induced colitis in rats.
abstract: Chronic intestinal inflammation contributes to an increased risk of colon cancer. Lactosucrose (LS), a kind of functional trisaccharide, can modulate immunity and promote microbe growth. The aim of this study was to investigate the effect of LS on 2,4,6-trinitrobenzene sulfonic acid (TNBS) induced colitis in rats. Rats were randomly divided into four treatment groups: the normal group, TNBS group, LS group, and salicylazosulfapyridine (SASP) group for five weeks. LS supplementation ameliorated TNBS-induced colitis. LS supplementation increased IL-10 production and suppressed the secretion of IL-12 in the colon, as compared to the TNBS group. LS decreased the production of TLR-2 protein and nuclear NF-κB p65 protein, as well as mRNA levels, as compared with colitic rats. These results indicate that chronic feeding of LS inhibited TNBS-induced chronic inflammation. LS has potential nutraceutical intervention to combat colitis.
authors.affiliation: State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China. ruanzheng@ncu.edu.cn.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Zheng
authors.initials: Z
authors.lastname: Ruan
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Zhou
authors.forename: Xiaoliu
authors.initials: X
authors.lastname: Huang
authors.forename: Hua
authors.initials: H
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Cui
authors.initials: C
authors.lastname: Zhang
authors.forename: Shiqiang
authors.initials: S
authors.lastname: Liu
authors.forename: Zeyuan
authors.initials: Z
authors.lastname: Deng
authors.forename: Guoyao
authors.initials: G
authors.lastname: Wu
authors.forename: Yulong
authors.initials: Y
authors.lastname: Yin
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003092:Colitis / Q000178:diet therapy* / Q000378:metabolism / Q000473:pathology; D003106:Colon / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000178:diet therapy / Q000378:metabolism / Q000473:pathology; D016753:Interleukin-10 / Q000819:agonists / Q000378:metabolism; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D056692:Prebiotics; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D013047:Specific Pathogen-Free Organisms; D012460:Sulfasalazine / Q000627:therapeutic use; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014302:Trinitrobenzenesulfonic Acid; D014312:Trisaccharides / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005765:Gastrointestinal Agents; D056692:Prebiotics; C498145:Rela protein, rat; C495343:Tlr2 protein, rat; D051195:Toll-Like Receptor 2; D051996:Transcription Factor RelA; D014312:Trisaccharides; D016753:Interleukin-10; D018664:Interleukin-12; D012460:Sulfasalazine; C081752:galactosucrose; D014302:Trinitrobenzenesulfonic Acid